The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aPost-hoc analysis of pooled patient data from the phase 3 ESTEEM 1 and 2 studies and the phase 2 PSOR-005 study. Among patients with moderate to severe palmoplantar psoriasis at baseline (PPPGA score ≥3; 10.1% [n = 144/1,431]).
bP = 0.021.
OTEZLA cleared or almost cleared psoriasis on the palms and soles1
Baseline
Week 16 PASI-70 result
Individual results may vary.
*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.
BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PPPGA, Palmoplantar Psoriasis Physician Global Assessment.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.